Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 1/20 | 0.58 |
| ▸ | KRAS | P01116 | 1/20 | 0.58 |
| ▸ | CD274 | Q9NZQ7 | 11/20 | 0.39 |
| ▸ | PDCD1LG2 | Q9BQ51 | 3/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 8/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30222551 | 1.00 | HRAS (0.58) | HRASKRASCD274PDCD1LG2PDCD1 | |
| SCHEMBL21198035 | 0.93 | HRAS (0.51) | HRASKRASCD274PDCD1LG2PDCD1 | |
| SCHEMBL21202174 | 0.88 | HRAS (0.49) | HRASKRASCD274PDCD1LG2PDCD1 | |
| SCHEMBL21207202 | 0.85 | HRAS (0.50) | HRASKRASCD274PDCD1LG2JAK3 | |
| SCHEMBL30222583 | 0.85 | HRAS (0.50) | HRASKRASCD274PDCD1LG2JAK3 | |
| SCHEMBL30222588 | 0.84 | HRAS (0.59) | HRASKRASCD274PDCD1NAMPT | |
| SCHEMBL21206993 | 0.84 | HRAS (0.59) | HRASKRASCD274PDCD1NAMPT | |
| SCHEMBL21207104 | 0.84 | HRAS (0.66) | HRASKRASCD274PDCD1LG2PDCD1 | |
| SCHEMBL30913765 | 0.84 | HRAS (0.66) | HRASKRASCD274PDCD1LG2PDCD1 | |
| SCHEMBL29066259 | 0.84 | HRAS (0.62) | HRASKRASCD274PDCD1LG2PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | disclosed |
| US-20210009576-A1 | COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-01-14 | — | — | US | disclosed |
| WO-2019145718-A1 | COMPOUNDS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009576-A1 | COMPOUNDS | KRAS, NRAS, HRAS | HRAS 3/4885KRAS 1/4885CD274 3721/4885 |
| US-12024506-B2 | Compounds | KRAS, NRAS, HRAS | HRAS 3/4885KRAS 1/4885CD274 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.